---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-009299"
form_type: "8-K"
ticker: "ABEO"
cik: "0000318306"
company_name: "ABEONA THERAPEUTICS INC."
filed_at: "2026-03-09T23:59:59+00:00"
generated_at: "2026-05-15T18:18:13.626064+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Abeona reports building ZEVASKYN launch momentum; payer coverage reaches 80% of commercial lives

## Summary
- First patient treated with ZEVASKYN in Dec 2025; manufacturing resumed Jan 2026, multiple biopsies collected, additional scheduled.
- All major commercial payers (United Healthcare, Cigna, Aetna, Anthem, most BCBS) now cover ZEVASKYN, representing ~80% of commercial lives.
- CMS established permanent HCPCS J-code (J3389) effective Jan 1, 2026; coverage also secured across all Medicaid programs.
- Initial Qualified Treatment Centers gaining familiarity with administrative processes; growing patient and physician interest.

## SEC filing metadata
- accession: 0001493152-26-009299
- form_type: 8-K
- ticker: ABEO
- cik: 0000318306
- company_name: ABEONA THERAPEUTICS INC.
- filed_at: 2026-03-09T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/318306/000149315226009299/0001493152-26-009299-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/318306/000149315226009299/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-009299
- JSON: https://secwatch.observer/filing/0001493152-26-009299.json
- Plain text: https://secwatch.observer/filing/0001493152-26-009299.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.